33rd week of 2013 patent applcation highlights part 41 |
Patent application number | Title | Published |
20130209465 | Stabilized Aqueous Antibody Compositions - The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/m L and a stabilizing amount of polyethyleneimine. | 2013-08-15 |
20130209466 | COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS - Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10 | 2013-08-15 |
20130209467 | METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS - Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone. | 2013-08-15 |
20130209468 | Use of MIF and MIF Pathway Agonists - The present invention relates to novel methods and compositions for increasing AMPK activity and glucose uptake comprising administering a macrophage migration inhibitory factor (MIF) pathway agonist in a subject in need thereof. The invention also relates to methods for selecting a subject for treatment with an agonist of MIF, identifying a subject at risk for developing a condition in which increased AMPK activity is desirable, and for predicting whether a subject is susceptible to a condition in which increased AMPK activity is desirable. | 2013-08-15 |
20130209469 | ANTIBODIES THAT BIND IL-4 AND/OR IL-13 AND THEIR USES - The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis. | 2013-08-15 |
20130209470 | ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation. | 2013-08-15 |
20130209471 | DC-STAMP ANTIBODIES - Provided herein are antibodies that specifically bind an epitope of DC-STAMP. Specifically, provided herein are monoclonal antibodies that bind an epitope of DC-STAMP, wherein the epitope comprises the amino acid sequence Glu-Val-His-Leu-Lys-Leu-His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:1). Optionally, the epitope comprises the amino acid sequence His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:2). Optionally, the epitope comprises the amino acid sequence Lys-Gln-Gly-Thr-Gln (SEQ ID NO:3). | 2013-08-15 |
20130209472 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARAGINYL TRNA SYNTHETASES - Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications. | 2013-08-15 |
20130209473 | R-SPONDIN TRANSLOCATIONS AND METHODS USING THE SAME - Provided are therapies related to the treatment of pathological conditions, such as cancer. | 2013-08-15 |
20130209474 | WISE/SOST NUCLEIC ACID SEQUENCES AND AMINO ACID SEQUENCES - The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways. | 2013-08-15 |
20130209475 | DKK1 ANTIBODIES AND METHODS OF USE - The present invention provides antibodies and immunologically functional fragments thereof that specifically bind DKK1 polypeptides. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases are also disclosed. | 2013-08-15 |
20130209476 | TREATMENT OF INFLAMMATORY DISORDERS - A method is provided for treating certain inflammatory disorders by inhibiting cadherin-11 function using a cadherin-11 antagonist. | 2013-08-15 |
20130209477 | AGENTS AND METHOD FOR TREATING INFLAMMATION-RELATED CONDITIONS AND DISEASES - Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. | 2013-08-15 |
20130209478 | FORMULATION COMPRISING AN ANTIBODY AGAINST P-SELECTIN - This invention relates to a pharmaceutical formulation of an antibody against P-Selectin, a process for the preparation of the formulation and uses of the formulation. | 2013-08-15 |
20130209479 | CANCER TREATMENT - The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subject's response to a cancer treatment. | 2013-08-15 |
20130209480 | METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS - The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof). | 2013-08-15 |
20130209481 | Anti-Tumor Antigen Antibodies and Methods of Use - Antibodies that bind to tumor associated antigen CD44 or to tumor associated antigen EphA2, are disclosed herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies, diagnostics, and screening methods. | 2013-08-15 |
20130209482 | MONOCLONAL ANTIBODIES TO BASIC FIBROBLAST GROWTH FACTOR - The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. | 2013-08-15 |
20130209483 | CANNABIDINOID DERIVATIVES - The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer. | 2013-08-15 |
20130209484 | SELECTIVE AMPD2 INHIBITORS AND METHODS FOR USING THE SAME - The present invention provides compounds and compositions that modulate adenosine monophosphate deaminase (AMPD) and methods for using the same to treat a clinical condition associated with the metabolic syndrome or a disease associated with the metabolic syndrome. In particular, the present invention provides a compound and a composition comprising a selective AMPD2 inhibitor and methods for using the same, for example, to treat a clinical condition associated with metabolic syndrome as well as diseases manifested by the metabolic syndrome. | 2013-08-15 |
20130209485 | THERAPEUTIC AGENT OF NON-ALLERGIC AIRWAY INFLAMMATION AND/OR NON-ALLERGIC HYPERRESPONSIVE AIRWAY - The invention provides a therapeutic agent for non-allergic airway inflammation and/or non-allergic airway hyperreactivity, containing a substance capable of inhibiting or eliminating the Th17 cell-like function of an IL-17RB positive NKT cells as an active ingredient; a prophylactic or therapeutic method for non-allergic airway inflammation and/or non-allergic airway hyperreactivity, using the substance, and a method of screening for a therapeutic agent for non-allergic airway inflammation and/or non-allergic airway hyperreactivity, containing a step of measuring a Th17 cell-like function of IL-17RB positive NKT cells. | 2013-08-15 |
20130209486 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 2013-08-15 |
20130209487 | Treatment of Avian Species with Inhibitors of P110 Delta Signaling - The invention includes compositions and methods for regulating p110 delta in an avian species. The invention includes inhibiting p110 delta, a component of p110 delta signaling pathway, or any combination thereof in an avian species as an anti-viral therapeutic approach for treating virus infection. | 2013-08-15 |
20130209488 | METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY - The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent. | 2013-08-15 |
20130209489 | Antibodies That Bind Myostatin, Compositions And Methods - There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them. Neutralizing antibodies recognizing the conformational epitope near position 21 to 31 and position 50 to 60. | 2013-08-15 |
20130209490 | Diagnostic BioMarkers for Fibrotic Disorders - The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10. | 2013-08-15 |
20130209491 | METHODS OF GENERATING ANTIBODIES TO METALLOENZYMES - A method of generating an antibody which inhibits a metalloenzyme is disclosed. The method comprises immunizing a subject with:
| 2013-08-15 |
20130209492 | Anti-Tie2 Antibodies and Uses Thereof - The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis. | 2013-08-15 |
20130209493 | BIOMAKERS FOR CIRCULATING TUMOR CELLS - Provided are methods for detecting circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject. | 2013-08-15 |
20130209494 | ENEDIYNE COMPOUNDS, CONJUGATES THEREOF, AND USES AND METHODS THEREFOR - Enediyne compounds having a structure according to formula (I), where R | 2013-08-15 |
20130209495 | ErbB3 ANTIBODIES - Antibodies are disclosed which bind to ErbB3 protein and further possess any one or more of the following properties: an ability to reduce heregulin-induced formation of an ErbB2-ErbB3 protein complex in a cell which expresses ErbB2 and ErbB3; the ability to increase the binding affinity of heregulin for ErbB3 protein; and the characteristic of reducing heregulin-induced ErbB2 activation in a cell which expresses ErbB2 and ErbB3. | 2013-08-15 |
20130209496 | Synergistic Effects Between Auristatin-Based Antibody Drug Conjugates And Inhibitors Of The PI3K-AKT mTOR Pathway - The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway. | 2013-08-15 |
20130209497 | WHOLE EGG PROTEIN PEPTIDES, PREPARATION METHOD AND USE THEREOF - Provided are whole egg protein peptides and the preparation method thereof, wherein the whole egg protein peptides are obtained by adopting compound proteases composed of pawpaw protease, fig protease and pineapple protease to enzymatically hydrolyze the whole egg protein powder. The whole egg protein peptides can be used for manufacture of products for enhancing immunity. | 2013-08-15 |
20130209498 | Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease - Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E | 2013-08-15 |
20130209499 | VACCINES FOR USE IN THE PROPHYLAXIS AND TREATMENT OF INFLUENZA VIRUS DISEASE - Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject. | 2013-08-15 |
20130209500 | IMMUNOGENIC COMPOSITIONS COMPRISING MYCOBACTERIUM TUBERCULOSIS POLYPEPTIDES AND FUSIONS THEREOF - The present invention relates to compositions and fusion proteins containing at least two | 2013-08-15 |
20130209501 | Immunogenic Compositions of Staphylococcus Epidermidis Polypeptide Antigens - The present invention relates to immunogenic compositions, comprising polypeptides isolated from | 2013-08-15 |
20130209502 | ALUMINA NANOPARTICLE BIOCONJUGATES AND METHODS OF STIMULATING AN IMMUNE RESPONSE USING SAID BIOCONJUGATES - Disclosed are nanoparticle-autophagosome conjugates capable of stimulating an immune response against a target antigen, wherein the nanoparticle-autophagosome conjugates include autophagosome(s) covalently attached to alumina nanoparticle(s), wherein the autophagosome includes defective ribosomal products (DRiPs) of the target antigen. Also disclosed are immunogenic compositions including these conjugates and/or antigen-presenting cells loaded with these conjugates, and methods of stimulating an immune response against a target antigen by administration of immunogenic compositions including these conjugates and/or antigen-presenting cells loaded with these conjugates. | 2013-08-15 |
20130209503 | METHOD FOR STABILIZATION OF BIOLOGICAL MOLECULES - Thermostable polysaccharide based lyophilized vaccines are disclosed, particularly polysaccharide-protein conjugate vaccines and methods for preparation thereof. In an exemplary embodiment, a stabilized vaccine composition consists essentially of at least one polysaccharide-protein conjugate, at least one amorphous excipient, and a buffer component. | 2013-08-15 |
20130209504 | COSMETIC FORMULATION - Disclosed is a topical skin cleanser comprising | 2013-08-15 |
20130209505 | CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4- -CARBONYL)-AMINO]-PENTANOIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER - The invention provides a crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester or its tautomer. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases. | 2013-08-15 |
20130209506 | Recombinant Virus with Diminished Latency and Methods of Using Same - The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses. | 2013-08-15 |
20130209507 | Rotavirus Subunit Vaccines and Methods of Making and Use Thereof - The present invention provides Rotavirus antigenic polypeptides or antigens that elicit an immune response in animal or human against rotavirus, compositions comprising said rotavirus polypeptides, methods of vaccination against rotavirus, and kits for use with such methods and compositions. The invention further provide novel expression vectors for producing the vaccine antigenic polypeptides. | 2013-08-15 |
20130209508 | Compositions Containing Purine and Pyrimidine Nucleotsides, Peptides, and Manganese and Their Uses - The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide. The invention also provides methods of rendering bacteria in culture resistant to ionizing radiation (IR), with these methods comprising culturing the bacteria in the presence of a radiation-protective composition. | 2013-08-15 |
20130209509 | H3 EQUINE INFLUENZA A VIRUS - The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. | 2013-08-15 |
20130209510 | METHODS FOR PREPARING SQUALENE - An improved method for preparing squalene from a squalene-containing composition, said method comprising the steps of (a) a purification distillation carried out at a temperature T | 2013-08-15 |
20130209511 | Recombinant Poxviral Vectors Expressing both Rabies and OX40 Proteins, and Vaccines Made Therefrom - The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus | 2013-08-15 |
20130209512 | UNIVERSAL INFLUENZA A VACCINES - Universal flu vaccines are disclosed. The vaccines induce broad and sustained protection against a wide range of influenza A viruses, reduce the need for annual vaccination campaigns with vaccines based upon viral strains predicted to be the predominant circulating strains, and ameliorate the threat of future pandemics that can potentially kill millions. | 2013-08-15 |
20130209513 | COMPOSITIONS, METHODS AND USES FOR POXVIRUS ELEMENTS IN VACCINE CONSTRUCTS AGAINST INFLUENZA VIRUS SUBTYPES OR STRAINS - Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions having two or more influenza gene segments. In other embodiments, vaccine compositions are reported of use in a subject. | 2013-08-15 |
20130209514 | APTAMER-TARGETED COSTIMULATORY LIGAND APTAMER - Compositions for inducing or enhancing immunogenicity of a tumor comprise bi- and multi-specific aptamers binding to a tumor cell and an immune cell. These compositions have broad applicability in the treatment of many diseases, including cancer. | 2013-08-15 |
20130209515 | ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS - The present invention provides pharmaceutical compositions and methods that include the use of anti-infective compounds that potentiate the host-immune response or limit or prevent the expression or activity of individual virulence factors. In addition, the compositions have immunomodulatory activity, and therefore can be used to prime host defenses to prevent or limit bacterial, fungal, and viral viability. In the compositions and methods of the inventions, specific steps of the bacterial-, fungal-, or viral-host interaction are targeted to prevent pathogenesis (e.g., infection). Such an approach should prevent pathogenic organisms from acquiring resistance to the protective anti-infective compounds. | 2013-08-15 |
20130209516 | IMMUNOMODULATORY COMPOSITIONS - Isolated immunomodulatory (e.g. immunostimulatory) polyhydroxlated pyrrolizidine compounds having the formula (I), wherein R is selected from the group comprising hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g. cycloalkyl), alkenyl, alkynyl and aryl groups, or a pharmaceutically acceptable salt or derivative thereof, are useful in therapy and prophylaxis, including increasing the Th1:Th2 response ratio, haemorestoration, alleviation of immuno-suppression, cytokine stimulation, treatment of proliferative disorders (e.g. cancer), vaccination, stimulation of the innate immune response and boosting of the activity of endogenous NK cells. | 2013-08-15 |
20130209517 | CANCER THERAPY - The present invention relates to a method of preventing, treating or inhibiting the development of tumors or metastases in a subject and to an immunomodulator for use in such therapy, in combination with a chemotherapeutic agent. An aspect the present invention is a method of preventing, treating, reducing, inhibiting and/or controlling the formation or establishment of metastasis of a primary neoplasia, tumor or cancer at one or more sites distinct from a primary neoplasia, tumor or cancer, in a subject intended to undergo chemotherapy, wherein the method comprises administering to the subject, a therapeutically effective amount of an antimetabolite pyrimidine analogue and an immunomodulator. | 2013-08-15 |
20130209518 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 2013-08-15 |
20130209519 | FORMULATIONS OF FLIBANSERIN - The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin. | 2013-08-15 |
20130209520 | FOAMS, INCLUDING MICROCELLULAR FOAMS, CONTAINING COLLOIDAL PARTICULATES - The present invention generally relates to foams and particles made from such foams, for applications such as drug delivery. The foams or particles may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foams may include colloidal particulates. A first aspect of the present invention is generally related to polymer-based foams or particles containing pharmaceutically active agents. In some cases, the foam or particle may contain smaller colloidal particulates therein. Such colloidal particulates may be used, for example, to limit the amount of material within certain regions of the foam, or exclude pharmaceutically active agents from being located within certain portions of the foam, which may useful for enhancing release of pharmaceutically active agents from the foam. In some cases, the colloidal particulates may cause the foam or particle to have an unexpectedly high specific surface area. The foam, in certain embodiments, can exhibit a relatively high loading of the pharmaceutically active agent. The foam may be microcellular in certain instances. The foam may also be created using a supercritical fluid, for example, supercritical C0 | 2013-08-15 |
20130209521 | NANOSTRUCTURED APREPITANT COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. | 2013-08-15 |
20130209522 | Drug Release from a Polymer-Controlled Local Antibiotic Delivery System Using a Degradable Bone Graft - In some embodiments, the invention provides an implant comprising a uniform mixture of degradable polymer, bone, and a drug. In some embodiments, the drug comprises an antibiotic. In some embodiments, diffusion of the drug from the implant at a therapeutic level is maintained for an amount of time longer than an amount of time that a pathogen is senescent. In some embodiments, diffusion of the drug from the implant at a therapeutic level is maintained for at least eight weeks, or at least ten weeks, or at least twelve weeks post-implantation. In some embodiments, the therapeutic level is maintained at an implantation site of the implant. | 2013-08-15 |
20130209523 | Amorphous Medicinal Fine Particles Produced By Pulsed Laser Ablation In Liquid And The Production Method Thereof - The present disclosure is directed to an in-liquid laser-based method for fabricating a solution of fine particles of amorphous solid medicinal compounds, a solution of fine particles of amorphous medicinal agents made with the method, and fine particles made with the method. By using a target solidified via a phase transition process to covert an initial crystalline structure into an amorphous solid, technical difficulties with handling a hydraulically-pressed target are overcome. The laser-based ablation process produces amorphous solid medicinal compound fine particles, which improves the bioavailability and solubility of the medicinal compound. The improvement results from a combination of: disordered crystalline structure and enlarged relative surface area by particle size reduction. The laser based method may be carried out with ultrashort pulsed laser systems, or with UV nanosecond lasers. Results obtained with an ultrashort near IR laser and a UV nanosecond laser show formation of amorphous solid curcumin fine particles. | 2013-08-15 |
20130209524 | METHOD OF USING AMNION ALLOGRAFT IN HEART TRANSPLANT SURGERY - Improved methods for heart transplant are described. The methods utilize an allograft comprising a layer of amnion to improve the performance and reduce complications of the heart transplant surgery and the allograft has a pre-made size and shape suitable for the application. | 2013-08-15 |
20130209526 | Flexible Bone Composite - The present invention relates in general to implantable flexible bone composites, and method for preparing the same. The flexible bone composite includes at least one polymeric layer and at least one calcium-containing layer. The polymeric layer can be a polymeric layer including a synthetic polymer. The calcium-containing layer can include a calcium compound such as β-Ca | 2013-08-15 |
20130209527 | PROCESS FOR THE PREPARATION OF WATER-IN-OIL AND OIL-IN-WATER NANOEMULSIONS - Process for the preparation of a water-in-oil or oil-in-water nanoemulsion wherein the dispersed phase is distributed in the dispersing phase in the form of droplets having a diameter ranging from 1 to 500 nm, comprising:
| 2013-08-15 |
20130209528 | USE OF EXOSOMES TO PROMOTE OR ENHANCE HAIR GROWTH - We describe the use of an exosome for the preparation of a pharmaceutical composition to promote or enhance would healing or hair growth, or both, in an individual. The exosome may be derived from a stem cell such as a mesenchymal stem cell (MSC). | 2013-08-15 |
20130209529 | PVA-BORONIC ACID CONTAINING COPOLYMER COMPOSITIONS FOR PROTEIN DELIVERY - Provided herein are phenylboronate containing co-polymers (PCC), compositions containing PCC and polyvinyl alcohol (PVA), such compositions further including proteins, methods of making these compositions by water in oil polymerization, and methods of using the protein containing compositions for releasing proteins. Such phenylboronate containing co-polymers are of Formula I: where m, n, p, x, R | 2013-08-15 |
20130209530 | "NANOPARTICLES FOR THE ENCAPSULATION OF COMPOUNDS, PREPARATION THEREOF AND USE OF SAME" - The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, comprising a casein matrix, a basic amino acid and a metal selected from a divalent metal, a trivalent metal and combinations thereof. Said nanoparticles can encapsulate a water soluble or fat soluble biologically active compound. The invention is applicable in the food, pharmaceutical and cosmetic sectors and in the nanotechnology sector. | 2013-08-15 |
20130209531 | APPLICATIONS OF PARTIALLY AND FULLY SULFATED HYALURONAN - Described herein is the use of partially and fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof for therapeutic and cosmetic applications as well as the treatment of a number of systemic, dermatological, periodontal, ophthalmic, and urological inflammatory diseases. | 2013-08-15 |
20130209532 | POLYSACCHARIDE GEL FORMULATION HAVING INCREASED LONGEVITY - Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. In some embodiments, the incorporating step comprises 1) mixing the at least one inhibitor with the at least one polysaccharide at a highly hydrated state thereby encapsulating the at least one inhibitor in a polysaccharide network, and 2) dehydrating the polysaccharide network thereby controlling release kinetics or final swell ratio. In another embodiment, the incorporating step comprises 1) encapsulating at least one inhibitor into a biocompatible or biodegradable vessel and 2) combining the polysaccharide and the vessel into a gel formulation. The polysaccharide gel formulations described herein can be used for a variety of cosmetic applications. | 2013-08-15 |
20130209533 | Solid Powder Cosmetic - A foundation and the like which contains latent means for masking skin dullness at the time of application thereof to the skin, the means gradually working a few hours after application, is provided by providing a solid powder cosmetic composition comprising the following ingredients (1) to (3): (1) an interference pearlescent pigment having a reflectance of 30% or higher to visible light having a wavelength of 540 to 580 nm, which has been combined with one or more materials selected from unit polymethylmethacrylate, silicon dioxide, platy barium sulfate, zinc oxide, and aluminum chloride, in an amount of 1 to 8 mass %; (2) spherical powder particles in an amount of 8 to 30 mass %; and (3) an oil having a viscosity of 500 to 100,000 cps, as measured by means of a B-type viscometer at 30° C., in an amount of 1.5 to 5 mass %; the amounts being on the basis of the total amount of the composition. | 2013-08-15 |
20130209534 | Substrate Of Polymeric Material And Method Of Carrying Out Thereof - A substrate of polymeric material for wound care contains at least one oleous antimicrobial and/or helping tissue regeneration substance that is selected from Hyperforin, Adhyperforin, 1-3 Diapigenin, 11-8 Diapigenin, Rutin, Quercetin, Hypericin, Azadirachtin α-β, Nimbin, Nimbidin, Salanin, Gallic Acid, Gedunin and combinations thereof. | 2013-08-15 |
20130209535 | WATERBORNE COATING COMPOSITION CONTAINING LOW MOLECULAR WEIGHT POLYTRIMETHYLENE ETHER GLYCOL - The present disclosure is directed to a low VOC (volatile organic content) waterborne coating composition comprising low molecular weight polytrimethylene ether glycol. This disclosure is further directed to an antimicrobial coating layer formed from the coating composition comprising low molecular weight polytrimethylene ether glycol. The coating compositions can be used as interior and exterior top coats, basecoats, primers, primer surfacers and primer fillers. The low molecular weight polytrimethylene ether glycol can also be functioning as a coalescing agent. The disclosure is particularly directed to a coating composition comprising components derived from renewable resources. | 2013-08-15 |
20130209536 | ANTIMICROBIAL ELASTOMERIC ARTICLES - The present invention relates generally to methods of preparing antimicrobial elastomeric articles that include an elastomeric article having an antimicrobial coating provided thereon. The antimicrobial elastomeric articles exhibit enhanced ability to reduce or eliminate microbes that come in contact with the article. Certain aspects of the invention are further directed to methods of packaging the antimicrobial elastomeric articles, where the packaged antimicrobial articles exhibit antimicrobial effectiveness for an extended period of time as compared to unpackaged antimicrobial articles. Antimicrobial elastomeric articles and packaged antimicrobial elastomeric articles prepared in accordance with the methods of the present invention are also provided. | 2013-08-15 |
20130209537 | CONTROLLED-RELEASE ANTIBIOTIC NANOPARTICLES FOR IMPLANTS AND BONE GRAFTS - The present invention relates to the preparation and use of antibiotic-containing nanoparticles for coating an implant including cranial implants and bone graft sites to provide for the extended release of antibiotics to treat infection. | 2013-08-15 |
20130209538 | BIODEGRADABLE OCULAR IMPLANT - The present invention relates to a biodegradable ocular implant for sustained drug delivery, comprising a first layer comprising a first biodegradable polymer, wherein the first layer contains a drug dispersed or dissolved therein. A multi-layered biodegradable ocular implant is also disclosed. | 2013-08-15 |
20130209539 | CORE SHEATH DRUG DELIVERY DEVICES - It relates to a device comprising (a) a core comprising polyurethane; (b) a sheath comprising ethylene vinyl acetate copolymer, said sheath substantially or completely surrounding said core; and (c) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath; and to a process for its preparation. | 2013-08-15 |
20130209540 | MULTI-LAYER NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITION - The invention provides a multi-layered pharmaceutical composition comprising two or more formulations with varying properties. In some embodiments, the pharmaceutical compositions provide combinations of different organoleptic properties within the same product. In certain embodiment, these combinations allow for a modified release profile of active ingredients as the user enjoys the pharmaceutical composition. The invention further provides methods for making and using the pharmaceutical composition. | 2013-08-15 |
20130209541 | IL-13 RECEPTOR BINDING PEPTIDES - A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13Rα2 protein. | 2013-08-15 |
20130209542 | PHARMACEUTICAL CARRIER AND PHARMACEUTICAL COMPOSITION FOR INHIBITING ANGIOGENESIS - A pharmaceutical carrier and a pharmaceutical composition for inhibiting angiogenesis are disclosed. The pharmaceutical carrier of the present invention comprises: a drug carrier; and a polypeptide linked to a surface of the drug carrier, wherein the polypeptide comprises a receptor binding domain of vascular endothelial growth factor. | 2013-08-15 |
20130209543 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS - The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability. | 2013-08-15 |
20130209544 | MICROVESICLES CARRYING SMALL INTERFERING RNAS, PREPARATION METHODS AND USES THEREOF - Microvesicles containing interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing interfering RNAs are also provided. Microvesicles containing interfering RNAs, pharmaceutical compositions and kits comprising such microvesicles can be used to study the effects of interfering RNAs on receptor cells. As microvesicles containing interfering RNAs can stably, high efficiently and specifically deliver interfering RNAs, microvesicles containing interfering RNAs can be used to treat related diseases. | 2013-08-15 |
20130209545 | TOPICAL THERAPEUTIC FORMULATIONS - The invention provides topical compositions and methods for using the compositions. The compositions can be used for the treatment of fibrotic or connective tissue disorders involving scarring, sub-dermal plaque accumulations, or fibrosis of muscle tissue. The disorders can be painlessly treated by the topical application of a composition described herein. One or more calcium channel blocker agents can serve as an active ingredient of the compositions, optionally in combination with, for example, one or more of emu oil and superoxide dismutase. The composition can further include pharmaceutically acceptable carriers that can facilitate the non-invasive transdermal delivery of the active(s) to subdermal sites. | 2013-08-15 |
20130209546 | COMBINATORIAL METHODS AND COMPOSITIONS FOR TREATMENT OF MELANOMA - The invention relates to combining targeted therapies with selected chemotherapeutics for the treatment of melanoma. The invention provides a method for inducing apoptosis in a melanoma tumor cell by reducing Akt3 activity. A method for inducing apoptosis in a melanoma tumor cell comprising contacting a melanoma tumor cell with an agent that reduces Akt3 activity to restore normal apoptotic sensitivity to a melanoma tumor cell, allowing a lower concentration of chemotherapeutic agents resulting in decreased toxicity to a patient. Also disclosed is a method for treating a melanoma comprising administering an agent that reduces Akt3 activity and an agent that reduces V599E B-Raf activity, thereby treating a melanoma tumor. | 2013-08-15 |
20130209547 | SUSTAINED RELEASE FORMULATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG - Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided. | 2013-08-15 |
20130209548 | SUSTAINED RELEASE FORMULATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG - Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided. | 2013-08-15 |
20130209549 | MATERIALS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES - The subject invention concerns materials and methods for treating neurodegenerative diseases and conditions associated with aggregation of the microtubule-associated protein tau. A method of the invention comprises administering an effective amount of a heat shock protein 27 (Hsp27), or a biologically-active fragment or variant thereof, or a polynucleotide encoding the same, to a person or animal in need of treatment. In one embodiment, a heat shock protein 27 (Hsp27), or a biologically-active fragment or variant thereof, is contacted with or provided to a target cell. The target cell can be a neuron. In a specific embodiment, an Hsp27 is delivered to the target cell via a polynucleotide encoding an Hsp27 protein, or a biologically-active fragment or variant thereof. In one embodiment, a method of the invention comprises injecting (e.g., via stereotaxic injection) a polynucleotide expression construct of the invention comprising a polynucleotide encoding an Hsp27 protein directly into neural tissue of a person or animal. The subject invention also concerns compositions comprising i) a heat shock protein 27, or a biologically-active fragment or variant thereof, and/or ii) a polynucleotide encoding an Hsp27, or a biologically-active fragment or variant thereof. The polynucleotide can be an expression construct that provides for expression of an Hsp27 in a target cell. | 2013-08-15 |
20130209550 | Anti-Viral Azide Containing Compounds - Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome. | 2013-08-15 |
20130209551 | PENTAPEPTIDE DERIVATIVES FOR PROMOTING HAIR GROWTH - The invention relates to substituted pentapeptide compounds of the formula R | 2013-08-15 |
20130209552 | ARIPIPRAZOLE COMPOSITIONS AND METHODS FOR ITS TRANSDERMAL DELIVERY - The present invention discloses compositions of liquid and gel formulation containing aripiprazole in the form of a patch for transdermal delivery. | 2013-08-15 |
20130209553 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF PRAMIPEXOLE - The present invention discloses an extended release pharmaceutical composition of pramipexole or salts thereof comprising at least 40% w/w of hydrogenated castor oil, and one or more pharmaceutically acceptable excipients. | 2013-08-15 |
20130209554 | NOVEL GELATIN CAPSULE COMPOSITIONS AND METHODS OF MAKING - A gelatin capsule composition that includes one or more first distinct regions comprising a gelatin and one or more second distinct regions comprising a water-insoluble rapid-release agent is provided. | 2013-08-15 |
20130209555 | Formulations and Dosage Forms of Oxidized Phospholipids - The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4′-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed. | 2013-08-15 |
20130209556 | DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM - DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented. | 2013-08-15 |
20130209557 | TAMPER RESISTANT DOSAGE FORM COMPRISING INORGANIC SALT - The invention relates to a pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing a pharmacologically active ingredient (A); an inorganic salt (B); and a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the inorganic salt (B) and the polyalkylene oxide (C) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (A) from said matrix comprises at least a time interval during which the release follows zero order kinetics. | 2013-08-15 |
20130209558 | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof - In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5, and wherein the pharmaceutically acceptable excipient is either a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide or a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer. The invention moreover relates to the above pharmaceutical composition for the above use wherein the dosage regimen comprises at least the administration of a dose of 100 to 600 mg/m2/per person of bendamustine on day 1 and day 2, optionally a dose of 50 to 150 mg/m | 2013-08-15 |
20130209559 | METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT - The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions. | 2013-08-15 |
20130209560 | ABUSE-RESISTANT FORMULATIONS - This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance. | 2013-08-15 |
20130209562 | METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY - Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug. | 2013-08-15 |
20130209563 | COMBINATION IMMEDIATE/DELAYED RELEASE DELIVERY SYSTEM FOR SHORT HALF-LIFE PHARMACEUTICALS INCLUDING REMOGLIFLOZIN - A combination immediate/delayed release delivery system for compounds which have short half-life's, such as the antidiabetic remogliflozin etabonate, is provided which provides a dosage form that has two distinct phases of release, a formulation that promotes immediate release of the compound upon ingestion and another formulation which delays the release of the compound so that a dosing regimen of remogliflozin etabonate, once daily, may be achieved while providing effective control of plasma glucose and minimizing the nighttime exposure of this compound. The delivery system includes, but is not limited to, a combination of enteric coating of an immediate release formulation such that a delay in release is provided. Methods for forming the so-described immediate/delayed release delivery system and using such delivery system for treating diabetes are also provided. | 2013-08-15 |
20130209564 | Polysaccharide Particle Vaccines - Particle compositions are prepared for use as polysaccharide particle vaccines. | 2013-08-15 |
20130209565 | POSOLOGY AND ADMINISTRATION OF GLUCOCORTICOID BASED COMPOSITIONS - The present invention relates to an improved method of administration of glucocorticoid based compositions in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimised individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic adrenal insufficiency. | 2013-08-15 |
20130209566 | NANOPARTICLE COMPOSITION AND METHODS TO MAKE AND USE THE SAME - The present invention provides a novel nanoparticle drug delivery system generated from poly(ortho ester) polymers with sustained drug release capability and can be functionalized to allow for systemic delivery to various organ systems throughout the body. One important aspect of this invention is that the nanoparticle drug delivery system generated from poly(ortho ester) polymers encapsulate several types of drugs in poly(ortho ester) nanoparticles, including but not limited to lipophilic, hydrophilic small and large molecules and also hydrophilic and lipophilic dyes by adopting appropriate emulsion techniques. These poly(ortho ester) nanoparticles are biodegradable, biocompatible and controlled release drug delivery system with zero order kinetics, which can be used in various biomedical applications such as eye-related diseases, cancer, arthritis, etc. | 2013-08-15 |